Pliant Therapeutics (PLRX) - רווח נקי למניה (EPS TTM)

Pliant Therapeutics focuses on developing long-term methods to combat tissue scarring. The company's rolling annual earnings per share on this GURU.Markets platform chart visualizes this status, where the value of -1.47 records the result. The developer is implementing AI software to automate cellular screening. Simultaneously, Pliant Therapeutics is expanding into lung and liver therapy markets to minimize scientific risks.

This indicator reflects the actual efficiency of capital management in the interests of shareholders. The formula calculates the portion of net income attributable to a single share, neutralizing time gaps between reporting periods. Analyzing the company's specific net income over 12 months allows for tracking the impact of share issuances and share buybacks on the value of the stake. For Pliant Therapeutics (PLRX), this metric is critical when scaling fibrosis therapy. Growth in this indicator would confirm the commercial success of drugs that block the proliferation of connective tissue.